The five-year initiative will boost domestic production of biologics and biosimilars, expand clinical trial capacity, and streamline drug approvals to move beyond generics.
India’s Next Pharma Leap: From Generics to Biologics
In a significant upgrade to India’s healthcare and pharmaceutical policy, Budget 2026 unveiled ‘Biopharma Shakti’, a ₹10,000 crore, five-year mission to transform India into a global biopharma manufacturing and R&D hub.
Finance Minister Nirmala Sitharaman said the programme aims to scale up domestic capacity in biologics, biosimilars, clinical research, and drug regulation—marking a strategic evolution from India’s traditional strength in generics.
“Biologic medicines are key to longevity and quality of life at affordable costs,” Sitharaman told Parliament, citing the rise in non-communicable diseases like diabetes, cancer, and autoimmune disorders.
Why Biologics, Why Now?
Biologics are complex therapies derived from living organisms, used in treating life-threatening and chronic diseases such as cancer, arthritis, and hormonal disorders. Unlike generic drugs, biologics and biosimilars require advanced biotech infrastructure, rigorous testing, and large-scale clinical trials.
Key drivers behind the initiative:
- India’s disease burden is shifting toward long-term, complex conditions
- Global demand for biologics is booming, expected to surpass $550 billion by 2030
- Biosimilars offer 30–50% lower cost than originator drugs, expanding access
- India imports many of these therapies despite being a generics powerhouse
“This is India’s chance to move up the value chain in global pharma,” said a senior executive at a leading biopharma company.
What Biopharma Shakti Will Deliver
The programme will fund development across four strategic pillars:
1. Manufacturing Ecosystem for Biologics & Biosimilars
- Scale up production of high-complexity biologic drugs
- Expand domestic biosimilar portfolio to reduce import dependence
- Incentivise public-private manufacturing partnerships
2. Clinical Trial Infrastructure
- Build a network of 1,000 accredited trial sites across India
- Attract global clinical research, especially for oncology and immunology
3. Regulatory Reforms
- Strengthen the Central Drugs Standard Control Organisation (CDSCO)
- Introduce a scientific review cadre for timely, high-quality drug approvals
- Align India’s regulatory timelines with global norms
4. Academic and R&D Backbone
- Establish three new NIPERs (National Institutes of Pharmaceutical Education and Research)
- Upgrade seven existing NIPERs to become biopharma innovation hubs
Biosimilars: A Cost-Effective Weapon Against Chronic Disease
Unlike small-molecule generics like paracetamol or atorvastatin, biosimilars mimic large, complex biologics such as:
- Trastuzumab for breast cancer
- Adalimumab for rheumatoid arthritis
- Erythropoietin for anaemia
- Insulin analogues for diabetes
These are not identical copies but are proven to be clinically equivalent, ensuring both access and affordability. Countries with strong biosimilar pipelines have cut treatment costs dramatically—something India aims to replicate domestically and export globally.
“We’ve mastered generics. Now we need to dominate biologics,” said a NIPER faculty member involved in biosimilar development.
Strategic Implications: Beyond Healthcare
Biopharma Shakti isn’t just a healthcare initiative—it aligns with broader goals of:
- Reducing healthcare import bills
- Creating high-skill employment in biotech and R&D
- Positioning India as a preferred manufacturing base for global biopharma firms
- Supporting Viksit Bharat 2047 through innovation-led health access
TL;DR
Budget 2026 launches ‘Biopharma Shakti’, a ₹10,000 crore plan to build India’s biologics and biosimilars ecosystem. The initiative will fund manufacturing, 1,000 clinical trial sites, regulatory upgrades, and new NIPERs, enabling India to lead the next wave of complex drug innovation.
AI summary:
- ₹10,000 crore Biopharma Shakti launched for 2026–2031
- Focus on biologics, biosimilars, and advanced drug manufacturing
- Will fund 1,000 clinical trial sites and strengthen CDSCO approval capacity
- Three new and seven upgraded NIPERs to support biopharma education/R&D
- Goal: Make India a global hub for complex, high-value therapeutics
